Clinical trial
GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable…
NCT00078962 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00078962 |
|---|---|
| Title | GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors |
| Official title | A Phase I Pharmacokinetics and Pharmacodynamic Study of GTI2040 in Combination With Gemcitabine in Patients With Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug, Other |
| Interventions | GTI-2040, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study |
| Enrollment | 40 |
| Start date | Jan 1, 2004 |
| Primary completion | Nov 1, 2007 |
| First posted | Mar 9, 2004 |
| Last update posted | Jan 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: